10-QPeriod: Q2 FY2023

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2023

Filed August 1, 2023For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported solid financial results for the second quarter of 2023, demonstrating robust revenue and income growth. Total revenue increased by 9.7% year-over-year to $943.6 million, driven primarily by strong performance in the Companion Animal Group (CAG) segment, which saw a 10.5% increase in revenue. This growth was fueled by recurring diagnostics revenue, higher realized prices globally, and increased volumes in the U.S. Net income attributable to IDEXX stockholders grew significantly by 69.9% to $224.2 million, or $2.67 per diluted share. This substantial increase reflects improved gross margins, driven by pricing strategies and operational efficiencies, as well as a significant decrease in research and development expenses compared to the prior year's acquisition-related costs. The company maintained a strong balance sheet with increased cash and cash equivalents and a healthy liquidity position, underscored by a significant available borrowing capacity under its credit facility.

Financial Highlights

53 data points
Beta

Revenue

$943.63M

60.7% Gross Margin

Net Income

$224.24M

23.8% Net Margin

EPS (Diluted)

$2.67

Total Assets

$2.87B

Cash & Equivalents

$132.84M

Free Cash Flow

$172.84M

Financial Statements
Beta
Revenue$943.63M
Cost of Revenue$370.78M
Gross Profit$572.85M
R&D Expenses$46.51M
Operating Income$296.14M
Interest Expense$10.54M
Net Income$224.24M
EPS (Basic)$2.70
EPS (Diluted)$2.67
Shares Outstanding (Basic)83.09M
Shares Outstanding (Diluted)83.98M

Key Highlights

  • 1Total revenue for the quarter rose 9.7% to $943.6 million, compared to $860.5 million in the prior year's second quarter.
  • 2Net income attributable to IDEXX stockholders surged by 69.9% to $224.2 million ($2.67 per diluted share), from $132.0 million ($1.56 per diluted share) in the prior year.
  • 3The Companion Animal Group (CAG) segment, the company's largest, saw revenue increase by 10.5% to $866.7 million, driven by recurring diagnostic revenue and price increases.
  • 4Gross profit margin improved to 60.7% from 59.7% in the prior year, supported by price gains, operational productivity, and favorable product mix.
  • 5Research and Development (R&D) expenses decreased significantly by 62.3% to $46.5 million due to a large prior-year acquisition-related expense, positively impacting operating income.
  • 6The company maintained a strong cash position, ending the quarter with $132.8 million in cash and cash equivalents, an increase from $112.5 million at the end of 2022.
  • 7Operating cash flow for the first six months of the year was $384.2 million, a substantial increase from $180.6 million in the prior year's comparable period.

Frequently Asked Questions

The primary driver of IDEXX's revenue growth was the strong performance of its Companion Animal Group (CAG) segment, which increased by 10.5%. This growth was attributed to higher realized prices globally and increased volumes in the U.S., particularly in recurring diagnostic revenue streams like consumables and reference laboratory services.

IDEXX experienced a significant improvement in profitability. Net income attributable to stockholders increased by 69.9% to $224.2 million, and diluted earnings per share grew to $2.67 from $1.56 in the prior year's second quarter. This was supported by a higher gross profit margin and a substantial reduction in research and development expenses.

IDEXX maintains a healthy financial position. Cash and cash equivalents increased to $132.8 million. The company also has significant liquidity with $984.5 million in available borrowing capacity under its $1.25 billion Credit Facility, and it was in compliance with its financial covenants, including a consolidated leverage ratio below 3.5-to-1.

A notable change was the significant decrease in Research and Development (R&D) expenses, down 62.3% year-over-year to $46.5 million. This was primarily due to a large acquisition-related R&D charge in the prior year's second quarter. Sales and marketing expenses increased due to investments in global commercial capabilities and higher personnel costs, while general and administrative expenses also saw an increase due to personnel-related costs.